- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Lipitor may be the first statin to switch to OTC
- Senate passes Drug Quality and Security Act
- Diplomat becomes distributor of recently approved cancer drug
SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and Xenoport for treating restless legs syndrome, the agency said Thursday.
The FDA approved Horizant (gabapentin enacarbil) as a once-daily treatment for moderate-to-severe RLS.
“People with restless legs syndrome can experience considerable distress from their symptoms,” FDA Division of Neurology Products director Russell Katz said. “Horizant provides significant help in treating these symptoms.”